How Do You Choose a Second-Line Treatment Option for Depression?

被引:1
|
作者
Weisler, Richard H. [1 ,2 ]
机构
[1] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA
[2] Duke Univ, Dept Psychiat, Durham, NC 27706 USA
关键词
ANTIDEPRESSANT THERAPY; POSTSTROKE DEPRESSION; MYOCARDIAL-INFARCTION; SEXUAL DYSFUNCTION; CARDIAC MORTALITY; SSRIS; RISK; AUGMENTATION; MEDICATION; BUPROPION;
D O I
10.4088/JCP.9104su1c.04
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
A majority of patients with major depression do not remit or adequately respond to initial antidepressant therapy. When response is insufficient, a diagnosis of depression and any comorbidities should be confirmed, treatment adherence should be established, and antidepressant dosages should be optimized as tolerated. If response is still insufficient, then implementing second-line treatment strategies is warranted. Second-line strategies of switching to or combining/augmenting the initial agent with one of a variety of antidepressant medications and/or psychotherapies improves remission rates, although no single approach or agent has demonstrated clear superiority over any other. Second-line treatment selections should be driven by safety considerations, patients' symptom profiles, and patient preference. Comorbid medical conditions, especially cardiac and cerebrovascular complications, and potential drug-drug interactions should be considered when making treatment decisions. (J Clin Psychiatry 2010;71[suppl 1]:21-26)
引用
收藏
页码:21 / 26
页数:6
相关论文
共 50 条
  • [41] Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?
    M. A. Pantaleo
    M. Di Battista
    F. Catena
    M. Astorino
    M. Saponara
    V. Di Scioscio
    D. Santini
    G. Piazzi
    P. Castellucci
    G. Brandi
    G. Biasco
    Journal of Cancer Research and Clinical Oncology, 2008, 134 : 625 - 630
  • [42] HOW DO STUDENTS CHOOSE ELECTIVES - YOU MAY BE SURPRISED
    HURLEY, JT
    SCHOOL AND COMMUNITY, 1971, 57 (05): : 34 - &
  • [43] COMPUTERIZING THE PERSONNEL DEPARTMENT - HOW DO YOU CHOOSE A VENDOR
    CERIELLO, VR
    PERSONNEL JOURNAL, 1984, 63 (12) : 32 - 38
  • [44] Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
    Cosman, Felicia
    Dempster, David W.
    CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (02) : 189 - 205
  • [45] Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
    Felicia Cosman
    David W. Dempster
    Current Osteoporosis Reports, 2021, 19 : 189 - 205
  • [46] What to do Next? Second-line Antiretroviral Therapy
    María Inés Figueroa
    Omar Sued
    Pedro Cahn
    Current Treatment Options in Infectious Diseases, 2014, 6 (2) : 159 - 170
  • [47] AXIS trial data confirm axitinib as second-line option for mRCC
    Sarah Payton
    Nature Reviews Urology, 2013, 10 (6) : 308 - 308
  • [48] Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option
    Aldo Castagnari
    BMC Proceedings, 2 (Suppl 2)
  • [49] Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
    Aprile, Giuseppe
    Negri, Francesca V.
    Giuliani, Francesco
    De Carlo, Elisa
    Melisi, Davide
    Simionato, Francesca
    Silvestris, Nicola
    Brunetti, Oronzo
    Leone, Francesco
    Marino, Donatella
    Santini, Daniele
    Dell'Aquila, Emanuela
    Zeppola, Tea
    Puzzoni, Marco
    Scartozzi, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 115 : 1 - 12
  • [50] Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
    De Luca, Emmanuele
    Marino, Donatella
    Di Maio, Massimo
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3721 - 3729